Brussels: European lawmakers cleared the path in mid-2026 for a law meant to end the chronic shortages of critical medicines that have left pharmacies rationing antibiotics, insulin, and painkillers across the continent.

The Critical Medicines Act, on which the Council and Parliament struck a provisional deal on 12 May 2026, aims to secure supply by rebuilding manufacturing inside the Union. The text still needs formal adoption after legal-linguistic revision, but negotiators say the political fight is settled.

The case for acting is stark. A Commission study found that more than half of recent critical medicines shortages stemmed from manufacturing problems, made worse by Europe’s heavy dependence on active pharmaceutical ingredients from India and China. When a single overseas plant stumbles, European shelves empty within weeks.

The new rules push in several directions at once. They give incentives to make medicines and their active ingredients on European soil, they help governments diversify away from single suppliers, and they make it easier for countries to buy together rather than compete against each other for the same scarce vials.

Lawmakers also lowered the bar for collective buying. Member states can now trigger Commission-led joint procurement with five countries on board rather than nine, a change meant to let smaller states pool their weight and negotiate as a bloc for hard-to-source treatments.

Not everyone welcomes the shift. Health campaigners in Africa warned that steering production and supply toward Europe could tighten global markets for the same drugs, leaving lower-income countries competing with a wealthy bloc that has just written itself a procurement advantage.

Industry has its own reservations. Generic manufacturers, who supply most of the medicines at risk, run on thin margins and warn that reshoring costs more than the market will bear without lasting public support. They want the incentives paired with faster approvals and predictable pricing, or the factories the law envisions may never break ground.

The pandemic hangs over the whole debate. Empty shelves during COVID-19 and the scramble for masks and generics convinced many governments that resilience, not just the lowest price, has to guide how the Union buys and makes its medicines. The Critical Medicines Act is the clearest attempt yet to turn that lesson into durable law.

The Commission set out its reasoning on the Critical Medicines Act, while the Council detailed the negotiated terms in its provisional agreement.

The real test comes after adoption. Building factories and qualifying new suppliers takes years, and incentives on paper do not guarantee that firms will bring critical medicines production home. Whether Europe’s pharmacies stop rationing will depend on how fast the promise turns into plants.